Elevara explores CDK4/6 inhibition for the treatment of rheumatoid arthritis
Backed by $70m in Series A funding, Elevara Medicines has launched to advance its CDK4/6 inhibitor, which belongs to a…
News
Eli Lilly and NVIDIA to build pharma’s “most powerful” supercomputer
CPHI 2025: time for European biopharma to double down on innovation
FDA rejects Regeneron’s pre-filled Eylea HD syringes amid filling facility woes
GSK forges pact with Empirico for respiratory siRNA in $745m deal
Aldeyra reshuffles pipeline, culling asset despite Phase II success
Japan’s MHLW grants orphan status to Kyowa and Orchard’s MLD therapy
Lifecore and PolyPeptide link for US peptide manufacturing
